Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
PRELI domain-containing protein 1, mitochondrial (PRELID1), is a highly conserved mitochondrial intermembrane space (IMS) protein that is part of the PRELI domain-containing family. PRELID1 forms a complex with the chaperone TRIAP1; this complex is critical for mediating the shuttle of specific phospholipids, notably phosphatidic acid (PA), across the mitochondrial IMS. This transfer is essential for the biosynthesis and proper distribution of mitochondrial membrane lipids, impacting mitochondrial morphology, maintenance of membrane potential, respiratory chain activity, and overall cellular bioenergetics[3][4][5]. PRELID1 contains a conserved PRELI/LEA motif necessary for its function in mitochondrial structure stabilization and apoptotic resistance[4]. Mutations or deficiency in PRELID1 destabilize mitochondrial function and enhance susceptibility to apoptosis, highlighting its key cytoprotective role. To date, PRELID1 is not a therapeutic target for any approved drugs and has no known interacting small molecules. - PRELID1 is not a receptor, enzyme, transporter, or typical therapeutic target but a mitochondrial lipid transfer protein that operates in concert with TRIAP1[3][4][5]. - There are no reported drugs/biomarkers associated with PRELID1, and it is not currently used for patient selection or therapeutic monitoring. - No major direct safety or therapeutic target concerns are reported. - Disease connections are primarily indirect (mitochondrial health/cell death/cancer neuroprotection)[4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on PRELI domain-containing protein 1, mitochondrial (PRELID1).